Kilitch Drugs (India) Ltd is fundamentally an export factory for medicines, built on a simple, recurring approach: set up a manufacturing plant, get it certified by international regulators, and then fill it with orders from other pharmaceutical companies and government buyers across Africa, Asia, and beyond. Founded in 1978 and incorporated in 1992, the company has spent nearly four decades refining this model, starting with a base in Navi Mumbai and later replicating it with a dedicated antibiotics plant in Ethiopia. That approach - own the factory, secure the regulatory approvals, and sell to institutional B2B customers in emerging markets - explains everything else the business does.
Business segments
A single manufacturing engine, split across two geographies and one greenfield project, all producing pharmaceutical formulations for the same export-led, B2B customer base.
1. Sterile and oral formulations: contract manufacturing and branded exports from regulated Indian facilities
The Mumbai plant makes injectables, eye drops, and oral medicines under its own certifications and for other Indian pharma companies, with exports driving roughly two-thirds of total revenue.
- Built for sterile liquids and solids - the Mumbai unit houses dedicated lines for dry powders, ophthalmic products, and small-volume liquid ampoules and vials, covering the dosage forms that require the strictest contamination controls.
- Doubled down on eye drops - seeing rising demand, the company doubled its ophthalmic manufacturing capacity at the Mumbai plant for 2025-26, because eye drops require the same sterile production skills as injectables and open up new buyer categories.
- Makes medicines for bigger Indian names - the injectable business includes contract manufacturing for Indian pharmaceutical companies like Intas and Indoco Remedies, meaning Kilitch produces the drugs to their specifications and earns a manufacturing fee, while those companies handle the branding and marketing.
- Certifications unlock country access - the plant holds accreditations from regulators including WHO GMP, PPB Kenya, NAFDAC Nigeria, FDA Ghana, and MOH Sudan, and the company has invested in getting additional approvals from Burkina Faso and the Philippines, because each new certification opens a new government or institutional tender market.
- Uses loan licensees to stretch capacity - beyond its own factory, Kilitch partners with third-party manufacturers who produce drugs using Kilitch’s technical specifications and under its quality team’s oversight, so it can supply more customers without immediately building new lines.
2. Cephalosporin antibiotics: a dedicated East African manufacturing base serving government tenders
The Ethiopian subsidiary operates the largest cephalosporin plant in East Africa, built to capture local government supply contracts with built-in foreign-currency protection.
- A plant bigger than the local market - the Ethiopia facility has a total capacity of 26.4 million vials per year, against local demand of 16 million vials, so from day one it was sized to supply government tenders and eventually export to neighbouring African countries.
- Covers the cephalosporin range - the plant makes cephalosporins in tablets, capsules, injectables, and dry powders for suspensions and syrups, meaning it can supply a hospital or government buyer with every form of the antibiotic they need from a single source.
- The government absorbs the currency risk - the Ethiopian government provides 55% of the order value in foreign currency, which protects Kilitch from losses when the local Birr fluctuates against the dollar.
- Tenders create recurring revenue - the Ethiopian Pharmaceutical Supply Service awarded a USD 9.13 million supply tender and has planned to purchase injectables from local manufacturers, so the subsidiary is plugged into a predictable government procurement cycle rather than relying solely on volatile private-market sales.
- Indian expertise, Ethiopian production - the company staffs the plant with highly trained QA, QC, production, and engineering personnel from India who transfer their skills to Ethiopian employees, ensuring the quality standards match those of the Mumbai plant.
3. Pen greenfield complex: a multi-category manufacturing hub under construction
A 15-acre site south of Mumbai is being turned into four to six new manufacturing units, with the first block already operational, to reduce outsourcing and add capacity across tablets, injectables, eye drops, nasal sprays, and nutraceuticals.
- Bought land to build, not to rent - the company purchased approximately 15 acres in March 2022 on the Pen-Khopoli Highway, 73 km from its Mumbai office, so it could design a pharmaceutical complex from scratch rather than retrofit existing buildings.
- Planned capacities are specific and large - the complex is designed to produce roughly 260 million oral tablets, 31 million liquid injectable vials, 47 million liquid injectable ampoules, 21.4 million ophthalmic drops, and 21.4 million nasal drops per year, giving a clear picture of the volumes the company expects to add.
- Aims for the highest regulatory standards - the facility is being built to meet WHO, EU Standard Guidelines, and USFDA GMP requirements, which would allow it to sell into regulated markets that the current plants cannot access.
- The nutraceutical block is already running - the first phase reached final completion and the Nutraceutical Manufacturing Block commenced operations on June 17, 2026, so the project is beginning to contribute even as the remaining units are built out.
- Funded from the existing business - the approximately Rs. 100 crore project cost is being met mostly through internal accruals in phases, meaning the company is not taking on large external debt to build it.
Group structure and partners
A tightly held promoter group controls the listed Indian parent, which in turn owns a majority stake in the Ethiopian manufacturing subsidiary and a dormant Indian entity.
- Two subsidiaries, one active - Kilitch Estro Biotech PLC in Ethiopia manufactures and sells pharmaceuticals and is 78.09% owned following an additional USD 200,000 investment in January 2025; Monarchy Healthserve Private Limited in India is wholly owned but had no business operations during FY25.
- Promoters hold a commanding stake - the promoter group held 68.90% of total equity shares as of March 2020, giving them effective control over the company’s strategic direction.
- Listed on both major Indian exchanges - the company’s equity shares trade on the BSE and NSE, providing liquidity for minority shareholders.